Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.
CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Four tracked peers in related health information/services names show downside momentum (median move about -4.9%), suggesting broader sector pressure rather than an isolated move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Conference attendance | Positive | -3.2% | CEO investor meetings at LSI USA 2026 to discuss Nociscan progress. |
| Feb 05 | Shareholder letter | Positive | -12.6% | 2026 priorities, CLARITY trial timeline, cash runway and capital structure update. |
| Feb 03 | Commercial expansion | Positive | -2.1% | Agreement with Source Healthcare to integrate Nociscan and generate real-world data. |
| Jan 13 | Equity financing | Positive | -6.9% | Common-stock financing strengthening cash to <b>$21.6M</b> and extending runway to 2028. |
| Jan 08 | Outlook update | Positive | +42.1% | 2026 outlook, strong scan growth and cash of <b>$12.0M</b> supporting operations into H1 2027. |
Recent fundamentally positive updates have often been followed by negative price reactions, with only one strong positive move on an operational update.
Over the past few months, Aclarion has focused on strengthening its balance sheet and advancing Nociscan. A $10.4 million financing left the company with $21.6 million in cash and a debt-free balance sheet, extending runway into 2028. Operationally, management highlighted strong 2025 scan growth, expanded imaging centers and physician users, and progress in the CLARITY trial targeting an internal readout by Q3 2026. Despite these constructive milestones and investor outreach events, most prior news days saw share-price declines.
Market Pulse Summary
This announcement highlights Aclarion’s ongoing investor outreach and focus on Nociscan, its MR spectroscopy platform for chronic low back pain. In context, the company recently strengthened its balance sheet to $21.6M in cash with no debt, outlined a 300-patient CLARITY trial targeting an internal readout by Q3 2026, and reported strong scan volume growth. Key factors to monitor include trial enrollment progress, payer and provider adoption, and how effectively conference exposure translates into long-term institutional support.
Key Terms
biomarkers medical
augmented intelligence technical
mr spectroscopy medical
AI-generated analysis. Not financial advice.
BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA.
During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company’s progress advancing Nociscan, the company’s proprietary MR spectroscopy platform designed to help physicians identify painful discs in patients suffering from chronic low back pain.
“We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion,” said Brent Ness, CEO of Aclarion. “With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead.”
To schedule a 1-on-1 meeting with Mr. Ness during the ROTH conference, please email: ksmith@pcgadvisory.com.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected to be internally available at the end of Q3, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
When will Aclarion (ACON) present at the 38th Annual ROTH Conference in 2026?
What will Aclarion (ACON) discuss with investors at ROTH Conference March 2026?
How can investors schedule a one-on-one meeting with Aclarion CEO Brent Ness at ROTH 2026?
What is Nociscan and why will Aclarion (ACON) highlight it at the ROTH Conference?
What financial position will Aclarion (ACON) emphasize at the March 2026 ROTH Conference?
How can patients or providers find a Nociscan center after Aclarion’s ROTH participation?
